125 related articles for article (PubMed ID: 32653455)
1. Socioeconomic Status Is an Independent Prognostic Factor for Overall Survival in Patients With Multiple Myeloma: Real-World Data From a Cohort of 223 Patients.
Intzes S; Symeonidou M; Zagoridis K; Bezirgiannidou Z; Pentidou A; Vrachiolias G; Seimenis I; Kotsianidis I; Spanoudakis E
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):704-711. PubMed ID: 32653455
[TBL] [Abstract][Full Text] [Related]
2. Socioeconomic Status and Overall Survival Among Patients With Hematological Malignant Neoplasms.
Nielsen LH; Kristensen DT; Jakobsen LH; Bøgsted M; Gregersen H; Madsen J; Severinsen MT; Brøndum RF
JAMA Netw Open; 2024 Mar; 7(3):e241112. PubMed ID: 38436954
[TBL] [Abstract][Full Text] [Related]
3. Impact of Extended Treatment Interval on the Prognosis of Multiple Myeloma Patients: A Retrospective Study.
Sun C; Ye JN; Mao JJ; Ma KW; Zhou X
Oncol Res Treat; 2020; 43(11):592-604. PubMed ID: 33045715
[TBL] [Abstract][Full Text] [Related]
4. International prognostic index (IPI)--a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy.
Scudla V; Zemanova M; Minarik J; Bacovsky J; Ordeltova M; Indrak K; Budikova M; Dusek L; Farbiakova V
Neoplasma; 2006; 53(4):277-84. PubMed ID: 16830053
[TBL] [Abstract][Full Text] [Related]
5. Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy.
Cowan AJ; Stevenson PA; Libby EN; Becker PS; Coffey DG; Green DJ; Hyun TS; Fromm JR; Gopal AK; Holmberg LA
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1386-1391. PubMed ID: 29481870
[TBL] [Abstract][Full Text] [Related]
6. Low socioeconomic status is a poor prognostic factor for survival in stage I nonsmall cell lung cancer and is independent of surgical treatment, race, and marital status.
Ou SH; Zell JA; Ziogas A; Anton-Culver H
Cancer; 2008 May; 112(9):2011-20. PubMed ID: 18361399
[TBL] [Abstract][Full Text] [Related]
7. Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma.
Song GY; Jung SH; Kim K; Kim SJ; Yoon SE; Lee HS; Kim M; Ahn SY; Ahn JS; Yang DH; Kim HJ; Lee JJ
BMC Cancer; 2020 Aug; 20(1):803. PubMed ID: 32831058
[TBL] [Abstract][Full Text] [Related]
8. Socioeconomic status is independently associated with overall survival in patients with multiple myeloma.
Fiala MA; Finney JD; Liu J; Stockerl-Goldstein KE; Tomasson MH; Vij R; Wildes TM
Leuk Lymphoma; 2015; 56(9):2643-9. PubMed ID: 25651424
[TBL] [Abstract][Full Text] [Related]
9. Real world outcomes with Bortezomib Thalidomide dexamethasone and Cyclophosphamide Bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma Múltiple.
Schütz NP; Ochoa P; Duarte P; Remaggi G; Yantorno S; Corzo A; Zabaljauregui S; Shanley C; Lopresti S; Orlando S; Verri V; Quiroga L; García CA; Fernández V; Fantl D
Hematol Oncol; 2020 Aug; 38(3):363-371. PubMed ID: 32196120
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
[TBL] [Abstract][Full Text] [Related]
11. Socioeconomic status and survival outcomes in elderly cancer patients: A national health insurance service-elderly sample cohort study.
Jang BS; Chang JH
Cancer Med; 2019 Jul; 8(7):3604-3613. PubMed ID: 31066516
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients.
González-Calle V; Slack A; Keane N; Luft S; Pearce KE; Ketterling RP; Jain T; Chirackal S; Reeder C; Mikhael J; Noel P; Mayo A; Adams RH; Ahmann G; Braggio E; Stewart AK; Bergsagel PL; Van Wier SA; Fonseca R
Ann Hematol; 2018 Aug; 97(8):1453-1462. PubMed ID: 29623394
[TBL] [Abstract][Full Text] [Related]
13. Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma.
Jakob C; Sterz J; Liebisch P; Mieth M; Rademacher J; Goerke A; Heider U; Fleissner C; Kaiser M; von Metzler I; Müller C; Sezer O
Leukemia; 2008 Sep; 22(9):1767-72. PubMed ID: 18580957
[TBL] [Abstract][Full Text] [Related]
14. High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents.
Terpos E; Katodritou E; Roussou M; Pouli A; Michalis E; Delimpasi S; Parcharidou A; Kartasis Z; Zomas A; Symeonidis A; Viniou NA; Anagnostopoulos N; Economopoulos T; Zervas K; Dimopoulos MA;
Eur J Haematol; 2010 Aug; 85(2):114-9. PubMed ID: 20477863
[TBL] [Abstract][Full Text] [Related]
15. Survival for patients with invasive cutaneous melanoma among ethnic groups: the effects of socioeconomic status and treatment.
Zell JA; Cinar P; Mobasher M; Ziogas A; Meyskens FL; Anton-Culver H
J Clin Oncol; 2008 Jan; 26(1):66-75. PubMed ID: 18165642
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of the albumin-globulin ratio and albumin-globulin score in patients with multiple myeloma.
Cai Y; Zhao Y; Dai Q; Xu M; Xu X; Xia W
J Int Med Res; 2021 Mar; 49(3):300060521997736. PubMed ID: 33682516
[TBL] [Abstract][Full Text] [Related]
17. [Adverse effects of double-hit combining ISS-Ⅲ stage and 1q gain or del (17p) on prognosis of patients with newly diagnosed multiple myeloma].
Liu XL; Yang YP; Bai J; Yue TT; Yang PY; Zhang Y; Fan HQ; Li W; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):912-917. PubMed ID: 31856439
[No Abstract] [Full Text] [Related]
18. [Clinical characteristics of patients with multiple myeloma harboring 6q deletion].
Chen L; Sun CY; An BW; Yu JM; Zhao F; Zhang C; Hu Y
Zhonghua Xue Ye Xue Za Zhi; 2021 Aug; 42(8):642-645. PubMed ID: 34547869
[No Abstract] [Full Text] [Related]
19. LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens.
Chim CS; Sim J; Tam S; Tse E; Lie AK; Kwong YL
Eur J Haematol; 2015 Apr; 94(4):330-5. PubMed ID: 25135740
[TBL] [Abstract][Full Text] [Related]
20. Serum-free light chains combined with the Revised International Staging System could further distinguish the superior and inferior clinical outcome of multiple myeloma patients.
Du J; Lu J; Gao W; Liu J; He H; Li L; Li R; Zhou L; Jiang H; Chen W; Fu W; Hou J
Ann Hematol; 2020 Aug; 99(8):1779-1791. PubMed ID: 32594218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
